EUVIMEDObjevte EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC 4.0

Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study

Bogdan Bjelica iD, Camilla Wohnrade iD, Alma Osmanovic iD, Olivia Schreiber-Katz iD, Sonja Koerner, Katja Kollewe, Sebastian Haeckl iD, Maren Freigang iD, Isabell Cordts iD, Benedikt Becker iD, Charlotte Vogt iD, Mohamad Tareq Muhandes iD and 7 more

European Journal of Neurology · 2025

DOI: 10.1111/ene.70405 ↗

At a glance

Multizentrische Studie in European Journal of Neurology, 2025. Written by Bogdan Bjelica and 18 co-authors. Institution: Department of Neurology, Hannover Medical School, Hannover, Germany. Major MEDLINE topics: Oligonucleotides, Action Potentials, Muscular Atrophy, Spinal, Spinal Muscular Atrophies of Childhood. Cited 10 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

This study aimed to evaluate changes in compound muscle action potential (CMAP) amplitude in adults with spinal muscular atrophy (SMA) undergoing nusinersen treatment and its association with motor function improvements.

Methods

This multicenter study assessed median, ulnar, and peroneal CMAP over a follow‐up of up to 4.5 years using linear mixed models. Motor function was measured using the Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE). Correlations between CMAP and motor function scores were analyzed.

Results

Seventy‐eight patients (27 ambulatory, 51 non‐ambulatory) were included. Baseline ulnar CMAP ≥ 2.0 mV distinguished SMA type 3 from type 2 with 91.3% sensitivity and 88.9% specificity (AUC 0.96, 95% CI 0.92–1.0), while baseline median nerve CMAP ≥ 6.5 mV showed 91.7% sensitivity and 77.3% specificity (AUC 0.84, 95% CI 0.72–0.96). No significant changes over time were observed in median, ulnar, and peroneal CMAP amplitudes ( p > 0.05). CMAP trajectories did not differ between SMA types 2 and 3 ( p > 0.05). No significant difference in the change in RULM or HFMSE at any time point was observed between SMA patients with baseline median nerve CMAP < 5 mV and those with CMAP of ≥ 5 mV ( p > 0.05). No significant correlations were found between changes in median nerve CMAP and HFMSE or RULM ( p > 0.05).

Discussion

CMAP amplitudes remained stable during nusinersen treatment, with no differences in trajectories between SMA types 2 and 3. Our findings suggest that while CMAP amplitude correlates with disease severity, it may not serve as a sensitive biomarker of treatment response in adult SMA patients.

Subjects

MeSH terms (MEDLINE)

OligonucleotidesAction PotentialsMuscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodHumansFemaleMaleAdultMiddle AgedUlnar NerveYoung AdultMedian NervePeroneal Nerve

Author keywords

biomarkercompound muscle action potential (CMAP)neurophysiologynusinersenspinal muscular atrophy (SMA)

Substances

nusinersenOligonucleotides

Authors and institutions

  • Department of Neurology, Hannover Medical School, Hannover, Germany.
  • PRACTIS Clinician Scientist Program, Deans Office for Academic Career Development, Hannover Medical School, Hannover, Germany.
  • Essen Center for Rare Diseases (EZSE), University Hospital Essen, Essen, Germany.
  • Institute of Biostatistics, Hannover Medical School, Hannover, Germany.
  • Department of Neurology, Technische Universität Dresden and German Center for Neurodegenerative Diseases, Dresden, Germany.
  • Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.

ORCID profiles: Bogdan Bjelica, Camilla Wohnrade, Alma Osmanovic, Olivia Schreiber-Katz, Sebastian Haeckl, Maren Freigang, Isabell Cordts, Benedikt Becker, Charlotte Vogt, Mohamad Tareq Muhandes, René Günther, Marcus Deschauer, Matthias Tuerk, Martin Regensburger, Susanne Petri

Cite

APA

Bjelica, B., Wohnrade, C., Osmanovic, A., Schreiber-Katz, O., Koerner, S., Kollewe, K., Haeckl, S., Freigang, M., Cordts, I., Becker, B., Vogt, C., Muhandes, M. T., Günther, R., Deschauer, M., Koch, J. C., Tuerk, M., Regensburger, M., Neuwirth, C., & Petri, S. (2025). Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study. European Journal of Neurology. https://doi.org/10.1111/ene.70405

Vancouver

Bjelica B, Wohnrade C, Osmanovic A, Schreiber-Katz O, Koerner S, Kollewe K, et al. Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study. European Journal of Neurology. 2025. doi:10.1111/ene.70405

BibTeX
@article{Bjelica2025,
  author = {Bjelica, Bogdan and Wohnrade, Camilla and Osmanovic, Alma and Schreiber-Katz, Olivia and Koerner, Sonja and Kollewe, Katja and Haeckl, Sebastian and Freigang, Maren and Cordts, Isabell and Becker, Benedikt and Vogt, Charlotte and Muhandes, Mohamad Tareq and Günther, René and Deschauer, Marcus and Koch, Jan C and Tuerk, Matthias and Regensburger, Martin and Neuwirth, Christoph and Petri, Susanne},
  title = {Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70405}
}
Start for free →